Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Nok Corporation

Yuichi Suzuki

Noboru Yamamoto

Koki Kawano

Kunitoshi Takeda

Toshihiko Kaneko

Atsuhiko Kubota

Atsushi Sasaki

Mamoru Takaishi

Takafumi Motoki

Yoichi Kita

Tasuku Ishida

Koichi Ito

Noritaka Kitazawa

Keiko Takahashi

Kohshi Ueno

Yoshihiko Norimine

Tadashi Okabe

Manabu Matsunaga

Afzal Khan

Yoichi Iimura

Paschalis Dimopoulos

Teiji Kimura

Satoshi Nagato

Shinji Hatakeyama

Tetsuhiro Niidome

Tetsuyuki Teramoto

Asahi Kitagawa

Makoto Komatsu

Nobuaki Sato

Daisuke Shinmyo

Nobuyuki Kurusu

Yuki Ishihara

Koji Hagiwara

Yoichi Hagi

Manami Kimura

Yoshihisa Kaneda

Yukie Yoshikawa

Koshi Ueno

Miyuki Sakai

Hiroki Ishihara

Provided is a sealing material having abrasion resistance usable for even construction machinery operated under severe conditions while keeping mechanical strength thereof. The sealing material includes a fluorinated resin composition containing the following materials (1) and (2), and further containing the following material (3) or (4). The materials are: (1) fluorinated resin, (2) bronze, (3) tricobalt tetraoxide, (4) a composite metal oxide containing cobalt and aluminum, and further containing at least one of metals selected from the group of chromium, titanium, magnesium, calcium, and lithium. Preferably, the fluorinated resin is polytetrafluoroethylene. Further, the sealing material is usable for construction machinery.

Sealing material

Provided are a polyurethane elastomer composition excellent in the abrasion resistance and swelling resistance, and a bearing material formed of the polyurethane elastomer composition. The polyurethane elastomer composition contains a polyurethane elastomer of 100 parts by mass, polyethylene wax of 3&#x2dc;25 parts by mass, and paraffin wax of 1&#x2dc;10 parts by mass. Further, preferably the polyurethane elastomer composition contains a cobalt based compound of 0.1&#x2dc;10 parts by mass.

Polyurethane elastomer composition and bearing material

A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a single bond or the like, Z is a Calkylene group or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivatives

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein Ris a hydrogen atom; Ris an aromatic ring group, etc.; Ris a hydrogen atom, etc; Ris a hydrogen atom; Ris an oxepanyl group, etc.; Ris a hydrogen atom.

Pyrazoloquinoline derivatives

A compound represented by the general formula: wherein Ring A is a Caryl group or the like, L is &#x2014;NRCO&#x2014; or the like (wherein Ris a hydrogen atom or the like), Ring B is a Caryl group or the like, X is a Calkylene group or the like, Y is a Calkylene group or the like, Z is an oxygen atom or the like, Rand Rare each independently a hydrogen atom or the like, and R, R, Rand Rare independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A&#x3b2; production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A&#x3b2; and typified by Alzheimer-type dementia.

Fused aminodihydrothiazine derivative

The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein Rand Rare substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; Rrepresents a hydrogen atom or the like; and Rrepresents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.

Indole derivative having piperidine ring

The present invention provides a novel compound having a superior calcium antagonism, in particular, a neuron-selective calcium antagonism. Namely, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted Con hydrocarbon ring etc.; E indicates a single bond, a group represented by the formula &#x2014;CO&#x2014;, etc.; X indicates a single bond, an oxygen atom etc.; Rindicates a hydrogen atom, a halogen atom, a hydroxyl group etc.; and D, D, Wand Ware the same as or different from each other and each represents a single bond or an optionally substituted Calkylene chain.

Piperazine compound and pharmaceutical composition containing the compound

Condensed pyridine compounds represented by formula (I):wherein: Rand Rare, independently, hydrogen, lower alkyl, or lower alkoxy; Rrepresent an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

Certain 1,3-disubstituted isoquinoline derivatives

N,N-substituted cyclic amine derivatives

Nitrile compound

Fused pyridine derivatives

Growing community of inventors

Ibaraki, Japan

Yuichi Suzuki